MapLight Therapeutics (MPLT) Interest & Investment Income (2024 - 2025)
MapLight Therapeutics (MPLT) reported Interest & Investment Income of $2.5 million for Q4 2025, up 174.75% on a YoY basis from $899000.0 in Q4 2024, and up 59.46% sequentially from $1.5 million in Q3 2025.
MapLight Therapeutics (MPLT) Interest & Investment Income (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Interest & Investment Income data on file, last reported at $2.5 million in Q4 2025.
- For the quarter ending Q4 2025, Interest & Investment Income rose 174.75% year-over-year to $2.5 million; the trailing twelve-month figure through Dec 2025 stood at $6.0 million (changed N/A YoY), and the FY2025 full-year result was $5.5 million, up 22.51% from the prior year.
- Interest & Investment Income advanced to $2.5 million in Q4 2025, from $1.5 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $2.5 million in Q4 2025 to a low of $899000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | MapLight Therapeutics | 88.50 Mn | 88.50 Mn | - | 2.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.47 Mn |
| Sep 30, 2025 | 1.55 Mn |
| Dec 31, 2024 | 899,000.00 |
| Sep 30, 2024 | 1.08 Mn |